Clinical Trials Logo

Allergy and Immunology clinical trials

View clinical trials related to Allergy and Immunology.

Filter by:
  • None
  • Page 1

NCT ID: NCT06260956 Not yet recruiting - Clinical trials for Food Allergy in Infants

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

ESCAPE
Start date: September 2024
Phase: N/A
Study type: Interventional

Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.

NCT ID: NCT05394363 Recruiting - Obesity Clinical Trials

Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents

GenV
Start date: October 4, 2021
Phase:
Study type: Observational

Generation Victoria (GenV) is a longitudinal, population-based study of Victorian children and their parents that will bring together data on a wide range of conditions, exposures and outcomes. GenV blends study-collected, study-enhanced and linked data. It will be multi-purpose, supporting observational, interventional, health services and policy research within the same cohort. It is designed to address physical, mental and social issues experienced during childhood, as well as the antecedents of a wide range of diseases of ageing. It seeks to generate translatable evidence (prediction, prevention, treatments, services) to improve future wellbeing and reduce the future disease burden of children and adults. The GenV Cohort 2020s is open to all babies born over a two-year period, and their parents, residing in the state of Victoria Australia. The GenV Cohort 2020s is preceded by an Advance Cohort of babies born between 5 Dec 2020 and 3 October 2021, and their parents. This comprises all families recruited at GenV's Vanguard hospital (Joan Kirner Women's and Children's) and at birthing hospitals throughout Victoria as GenV scaled up to commence recruiting for the GenV Cohort 2020s. The Advance Cohort have ongoing and full participation in GenV for their lifetime unless they withdraw but may have less complete data and biosamples.

NCT ID: NCT05323357 Recruiting - Microbiota Clinical Trials

Bern Human Organoid-Study to Study Host-microbe Interaction

humorg
Start date: March 31, 2022
Phase:
Study type: Observational [Patient Registry]

The human body inhabits a complex consortium of different microbes which together form the microbiota. Virtually every surface of the human body is colonized by a distinct microbiota, forming complex communities. An increasing number of research results indicates that changes in the microbiota can have vast effects on the health of its host. Most studies investigating the microbiota were conducted on animals, as many interventions and investigations cannot be performed on humans due to ethical considerations. This raises the question if findings from experimental studies are translational and can benefit patients. That becomes especially apparent when trying to dissect molecular mechanisms involved in this fine-tuned interplay between nutrients, the microbiota, and its host. By establishing human organoid cultures from the large and small intestine that can be exposed to microbes and/or microbial products with subsequent transcriptomic, epigenetic and immunological analysis, the investigators aim to generate findings with high translational potential with new insights into the complex interaction of the microbiota, the host and its immune system.

NCT ID: NCT04916145 Completed - Clinical trials for Allergy and Immunology

An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy Adults

SAT-008
Start date: October 8, 2020
Phase: N/A
Study type: Interventional

The purpose of this exploratory study is to evaluate the efficacy, safety, and feasibility of a novel digital device called SAT-008 in healthy adults.

NCT ID: NCT04751760 Recruiting - Clinical trials for Allergy and Immunology

Feasibility Study of a New Immunoglobulin E (IgE) Assay Method

LuLISA
Start date: April 20, 2021
Phase:
Study type: Observational

The main objective is to study the feasibility of a new specific IgE assay using a bioluminescence technique in a pediatric and adult allergic population. For this, we will collect blood, and urine during a blood test scheduled for the follow-up of the patient.

NCT ID: NCT04523246 Completed - Clinical trials for Corona Virus Infection

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NH-Shingrix
Start date: September 1, 2020
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19.

NCT ID: NCT04438629 Recruiting - Infection Viral Clinical Trials

Evaluation of Immune Response in COVID-19 Patients

IMMUNOVID
Start date: March 26, 2020
Phase:
Study type: Observational

The aim of the project is to evaluate the immunological features of COVID-19 patients. Patients are recruited without any pharmacological treatments restriction. The number of samples is estimated on the basis of feasibility, that means on the maximum number of patients with COVID-19, who are expected to be able to be enrolled by the units involved. Based on the investigators' experience, gained in the onco-immunological field, considering the time and economic resources available, the investigators expect to enroll at least 80 patients.

NCT ID: NCT03763630 Completed - Asthma Clinical Trials

MAPS & ITEC Cohorts: 6-8 Years Follow-up

Start date: September 15, 2017
Phase: Phase 2
Study type: Interventional

This study represents the follow-up, age 6-8 years, of children recruited at birth into two cohorts. The first cohort, the Mite Allergen Prevention Study (MAPS) was a double-blind, randomized controlled trial of the use of house dust-mite immunotherapy in the primary prevention of atopy and asthma. The Immune Tolerance in Early Childhood (ITEC) cohort is a separate observational cohort following up infants at high risk of atopy and correlating atopic disease development with epigenetic markers.

NCT ID: NCT02559258 Terminated - Clinical trials for Allergy and Immunology

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Start date: August 2015
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose- escalation study in otherwise healthy cat-, dust mite-, or Bermuda grass-allergic male and female subjects. There will be five dosing cohorts (0.1, 0.3, 1.0, 3.0 and 10.0 mg/kg), with eight subjects in each cohort, randomized to either epsi-gam (6 subjects) or placebo (2 subjects) for a total of 40 subjects. The first cohort will receive the starting dose of 0.1 mg/kg epsi-gam or placebo and subsequent cohorts will be recruited sequentially to receive escalating doses of epsi-gam or placebo.